Literature DB >> 12923819

Intrastriatal serotonin 5-HT2 receptors mediate dopamine D1-induced hyperlocomotion in 6-hydroxydopamine-lesioned rats.

Christopher Bishop1, Dev P Kamdar, Paul D Walker.   

Abstract

Striatal dopamine (DA) and serotonin (5-HT) functions are altered following DA denervation. Previous research indicates that intrastriatal coadministration of D1 and 5-HT2 receptor agonists synergistically increase locomotor behavior in DA-depleted rats. In the present study, we examined whether striatal 5-HT2 mechanisms also account for supersensitive D1-mediated locomotor behavior following DA denervation. Adult male Sprague-Dawley rats were subjected to bilateral striatal cannulation and then received either intracerebroventricular (i.c.v.) or intrastriatal 6-hydroxydopamine (6-OHDA; 200 microg or 20 microg/side, respectively). After at least 3 weeks, i.c.v.-lesioned rats received intrastriatal infusions of the 5-HT2 receptor antagonist ritanserin (2.0 microg/side) or its vehicle (DMSO) followed by systemic SKF 82958, a D1 agonist (1.0 mg/kg, i.p.) and locomotor activity was monitored. In another experiment, intrastriatal sham and 6-OHDA-lesioned rats received bilateral intrastriatal infusions of ritanserin (2.0 microg/side) or its vehicle (DMSO) followed by intrastriatal infusions of SKF 82958 (5.0 microg/side) or vehicle (0.9% saline). Rats with DA loss demonstrated supersensitive locomotor responses to both systemic and intrastriatal SKF 82958. Ritanserin pretreatment blunted systemic SKF 82958-induced hyperlocomotion and returned intrastriatal D1-mediated hyperactivity to sham lesion levels. The results of this study suggest that striatal 5-HT2 receptors contribute to D1-mediated hyperkinesias resulting from DA loss and suggest a pharmacological target for the alleviation of dyskinesia that can develop with continued DA replacement therapy. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12923819     DOI: 10.1002/syn.10253

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  5 in total

1.  Effects of risperidone on dopamine receptor subtypes in developing rat brain.

Authors:  Taylor Moran-Gates; Christopher Grady; Young Shik Park; Ross J Baldessarini; Frank I Tarazi
Journal:  Eur Neuropsychopharmacol       Date:  2006-12-18       Impact factor: 4.600

2.  Plasticity within striatal direct pathway neurons after neonatal dopamine depletion is mediated through a novel functional coupling of serotonin 5-HT2 receptors to the ERK 1/2 map kinase pathway.

Authors:  Pierre Brown; Charles R Gerfen
Journal:  J Comp Neurol       Date:  2006-09-20       Impact factor: 3.215

3.  Delayed yet persistent effects of daily risperidone on activity in developing rats.

Authors:  Rachel M Stevens; Matthew A Gannon; Molly S Griffith; Mark E Bardgett
Journal:  Behav Pharmacol       Date:  2016-08       Impact factor: 2.293

4.  Differential regional and dose-related effects of asenapine on dopamine receptor subtypes.

Authors:  Frank I Tarazi; Taylor Moran-Gates; Erik H F Wong; Brian Henry; Mohammed Shahid
Journal:  Psychopharmacology (Berl)       Date:  2008-02-24       Impact factor: 4.530

5.  Ethanol-MDMA interactions in rats: the importance of interval between repeated treatments in biobehavioral tolerance and sensitization to the combination.

Authors:  Sami Ben Hamida; Erin Plute; Sonia Bach; Christine Lazarus; Antoine Tracqui; Christian Kelche; Anne Pereira de Vasconcelos; Byron C Jones; Jean-Christophe Cassel
Journal:  Psychopharmacology (Berl)       Date:  2007-03-08       Impact factor: 4.415

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.